CVRx, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular disease. The company’s primary product is Barostim, an implantable device that delivers electrical pulses to baroreceptors in the carotid artery to improve symptoms of heart failure with reduced ejection fraction (HFrEF). Barostim provides Baroreflex Activation Therapy (BAT), which complements guideline-directed medical therapy by modulating the autonomic nervous system. The device is FDA-approved for use in the U.S. and has received FDA Breakthrough Device designation. Clinical trials for Barostim have been conducted in the U.S., Germany, Italy, France, Canada, and the United Kingdom. The company targets patients with HFrEF who have not received adequate benefit from existing treatments, offering a minimally invasive alternative to more invasive device-based therapies such as Left Ventricular Assist Devices or heart transplants.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage cvrx.com
Sector Healthcare IR page ir.cvrx.com
Tags
neuromodulation, heart failure, cardiovascular disease, implantable devices, baroreflex activation therapy, autonomic nervous system, hfref, minimally invasive surgery, Barostim, BAT, BeAT-HF, HOPE4HF, BAT-in-HF
Press page —

Metrics

Valuation  
Market cap $ 49.849M
Market cap (USD) $ 49.849M
P/E -0.88
PEG —
P/BV 3.61
P/S 0.83
P/OCF -1.20
P/FCF -1.19
Dividend yield —
Turnover / mcap —
Returns  
ROE -96.6%
ROI -60.0%
ROIC -43.3%
Profit margin -94.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 424.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 56.651M 51.292M 39.295M 22.469M 13.036M 6.053M
Net profit -53.306M -59.965M -41.199M -41.428M -43.078M -14.109M
Free cash flow -40.75M -40.505M -39.612M -43.362M -28.915M -16.407M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 7.1 12.67 31.44 18.35 12.23 —
Price performance 12m -0.44 -0.6 0.71 0.5 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.28M 2.56M 5.5M 7.55M 9.27M 10.7M
↳ YoY growth +99.8% +115.0% +37.2% +22.7% +15.1%
↳ 5y CAGR +52.8%
Borrowings, current (USD) — 0.00 — — — — —
Borrowings, non-current (USD) — 19.3M 0.00 6.75M 29.2M 49.3M 49.5M
Lease liabilities (USD) — — 0.00 339,000 1.39M 1.16M 990,000
Cash and deposits (USD) 25.7M 59.1M 142M 106M 90.6M 106M 75.7M
Right-of-use assets (USD) — — 0.00 334,000 1.35M 1.07M 878,000
Net debt (borrowings + leases - cash) (USD) — -39.8M -142M -99.1M -60M -55.5M -25.2M
Cash flow detail
Operating cash flow (USD) — -16.1M -27.7M -42.7M -39M -39.1M -40.2M
Purchases of property, plant and equipment (USD) — -311,000 -1.18M -685,000 -591,000 -1.36M -580,000
Change in receivables (cash effect) (USD) — -562,000 -1.28M -2.94M -2.05M -1.72M -1.4M
Change in inventories (cash effect) (USD) — -1.27M -537,000 -3.08M -4.03M -1.12M -98,000
Change in payables (cash effect) (USD) — 46,000 27,000 1.21M 165,000 698,000 1.25M
Interest paid (cash effect) (USD) — -2.03M -1.71M -59,000 -1.4M -3.61M -5.05M
Income taxes paid (cash effect) (USD) — -10,000 -2,000 -5,000 -4,000 0.00 —
Share-based compensation (USD) — 132,000 1.91M 3.89M 6.3M 19.1M 11.1M
Operating cash flow before change in receivables (USD) — -15.5M -26.5M -39.7M -37M -37.4M -38.8M
Free cash flow (OCF - PPE - intangibles) (USD) — -16.4M -28.9M -43.4M -39.6M -40.5M -40.8M
Income detail
Research and development expense (USD) — 6.41M 7.5M 9.95M 11.6M 11.1M 11.1M
↳ 5y CAGR +11.7%
Total comprehensive income (USD) — -14.1M -43.1M -41.4M -41.2M -60M -53.3M
Comprehensive income to owners (USD) — -14.1M -43.1M -41.4M -41.2M -60M -53.3M
Reported Aug 9, 2021 Feb 22, 2022 May 2, 2022 Feb 10, 2023 Feb 9, 2024 Feb 18, 2025 Feb 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MINNEAPOLIS, November 5, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2026.

Recent Highlights

● Total revenue for the third quarter of 2026 was $13.8 million

● U.S. revenue for the third quarter of 2026 was $13.0 million

● Active implanting centers in the U.S. increased to 262 as of September 30, 2026, as compared to 250 as of September 30, 2025

● A second major Medicare Advantage provider has issued a coverage policy for Barostim, effective July 17, 2026, covering the current FDA-approved indication and patients enrolled in BENEFIT-HF.

Oct 22, 2026

PDF Version

MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact: Mark Klausner ICR Healthcare 443-213-0501 [email protected]

Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 [email protected]

News Release image

Sep 29, 2026

PDF Version

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix.

Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also be included in the clinical trial ePoster hub.

New REBALANCE Registry and Real-World HFmrEF Evidence In a late-breaking session, Dr. Dmitry Yaranov will present new analyses from the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, evaluating the safety and benefits of Barostim in commercial use.

In a separate rapid-fire session, Dr. Javed Butler will present Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden.

In addition to the REBALANCE and HFmrEF presentations, Barostim will be featured in numerous scientific sessions and activities throughout the HFSA Annual Scientific Meeting 2026.

Barostim on the HFSA Annual Scientific Meeting 2026 Agenda Friday, Oct. 9:

  • Devices in Heart Failure Meeting, Discussion Forum – Making a Choice CCM or Barostim (Dr. Elizabeth Volz and Dr. Omar Cantu Martinez)

  • Devices in Heart Failure Meeting, Trial Tinder: Choose my Trial! – BENEFIT-HF (Dr. Farooq Sheikh)

  • ePoster, Barostim Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) (Dr. William Abraham)

Saturday, Oct. 10:

  • Poster, Interaction Testing Between Barostim Neo Device and Assure Wearable Cardiac Defibrillator (Dr. Rhea Verma)

Sunday, Oct. 11:

  • Sunday Plenary Session, The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy (Dr. Dmitry Yaranov)

  • Rapid Fire Session 2, Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden (Dr. Javed Butler)

  • Poster, Optimizing Management of Heart Failure with Reduced Ejection Fraction Using Baroreflex Activation Therapy: A Path to Diuretic Independence (Dr. Shreya Srivastava)

Monday, Oct. 12:

  • Game of Thrones House of Devices: Restoring the Realm’s Failing Hearts, House Lannister: Barostim Takes Up Arms (Dr. Sarah Chuzi)

CVRx Sponsored Programs CVRx will host two symposia sharing insights on Barostim’s role in the heart failure care continuum and its integration into clinical practice.

On Friday, Oct. 9 from 7:00–8:30 a.m., Device-Based Neurohormonal Intervention: The Role of Barostim in Heart Failure Care will explore the clinical evidence supporting Barostim, patient selection, integration into guideline-directed care and practical considerations for implementation.

On Sunday, Oct. 11 from 1:00–2:00 p.m., Successful Barostim Program Development: A Critical Component of the Heart Failure Care Continuum will address multidisciplinary collaboration, patient identification, referral pathways, workflow integration and best practices for developing and sustaining a successful Barostim program.

“We are excited by the scientific interest in Barostim at this year’s HFSA conference, with four separate data sets, five podium discussions and two symposia focused on practical elements for incorporating Barostim into clinical practice,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “The data being presented provide important new scientific insights about Barostim across patient populations, clinical outcomes and real-world practice, contributing to a broader understanding of its role in the heart failure continuum.”

About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact: Mark Klausner or Mike Vallie ICR Healthcare 443-213-0501 [email protected]

Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 [email protected]

News Release image

Prompts

CVRx, Inc. (ticker CVRX), listed in United States.

ETFs Holding CVRx, Inc.

ETF Weight in ETF Shares Market value As of
EBI 0.00% 22 $ 65.12 Aug 31, 2026